These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27809914)

  • 41. Everolimus in adult tuberous sclerosis complex patients with epilepsy: Too late for success? A retrospective study.
    Stockinger J; Strzelczyk A; Nemecek A; Cicanic M; Bösebeck F; Brandt C; Hamer H; Intravooth T; Steinhoff BJ
    Epilepsia; 2021 Mar; 62(3):785-794. PubMed ID: 33534134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia.
    Leitner DF; Kanshin E; Askenazi M; Siu Y; Friedman D; Devore S; Jones D; Ueberheide B; Wisniewski T; Devinsky O
    PLoS One; 2022; 17(5):e0268597. PubMed ID: 35587487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus as adjunctive treatment in tuberous sclerosis complex-associated epilepsy in children.
    Svarrer EMM; Fischer CM; Frederiksen MG; Born AP; Hoei-Hansen CE
    Dan Med J; 2019 Dec; 66(12):. PubMed ID: 31791480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
    French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
    Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial.
    Curatolo P; Franz DN; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; de Vries PJ; Dlugos DJ; Fan J; Ridolfi A; Pelov D; Voi M; French JA
    Lancet Child Adolesc Health; 2018 Jul; 2(7):495-504. PubMed ID: 30169322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Efficacy and safety of rapamycin in treatment of children with epilepsy complicated with tuberous sclerosis].
    Zou L; Liu Y; Pang L; Ju J; Shi Z; Zhang J; Chen X; Su X; Hu L; Shi X; Yang X
    Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):812-6. PubMed ID: 25582464
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
    Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
    Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
    Davies M; Saxena A; Kingswood JC
    Orphanet J Rare Dis; 2017 Feb; 12(1):35. PubMed ID: 28202028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
    Curran MP
    Paediatr Drugs; 2012 Feb; 14(1):51-60. PubMed ID: 22136276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term treatment with everolimus in TSC-associated therapy-resistant epilepsies.
    Wiegand G; May TW; Lehmann I; Stephani U; Kadish NE
    Seizure; 2021 Dec; 93():111-119. PubMed ID: 34740140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
    Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
    Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
    Sadowski K; Kotulska K; Jóźwiak S
    Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
    Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
    Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study.
    Su R; Huang T; Gu L; Bao Y; Liu Z; Dao P; Yao L; Hu X; Fu G; Wu J; Tricard T; Wu G; Chen M; Li C; Huang Z; Zheng B; Chen Y; Xue W; Guo G; Dong P; Huang J; Zhang J
    Cancer Med; 2024 Sep; 13(17):e70181. PubMed ID: 39279295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Retinal astrocytoma regression in tuberous sclerosis patients treated with everolimus.
    Zipori AB; Tehrani NN; Ali A
    J AAPOS; 2018 Feb; 22(1):76-79. PubMed ID: 29277498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
    Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
    Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
    Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Whittemore VH; Thiele EA; Ford JP; Shah G; Cauwel H; Lebwohl D; Sahmoud T; Jozwiak S
    Lancet; 2013 Jan; 381(9861):125-32. PubMed ID: 23158522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.
    Overwater IE; Rietman AB; Mous SE; Bindels-de Heus K; Rizopoulos D; Ten Hoopen LW; van der Vaart T; Jansen FE; Elgersma Y; Moll HA; de Wit MY;
    Neurology; 2019 Jul; 93(2):e200-e209. PubMed ID: 31217257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature.
    Strzelczyk A; Grau J; Bast T; Bertsche A; Bettendorf U; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klotz KA; Kluger G; Knake S; Knuf M; Kurlemann G; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Rosenow F; Ruf S; Sauter M; Schäfer H; Schlump JU; Schubert-Bast S; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Zöllner JP
    Expert Rev Clin Pharmacol; 2021 Jun; 14(6):749-760. PubMed ID: 33792454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.